HeartBeam Management to Present at Key Investor and Medical Conferences in March 2026

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that its management team will participate in several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging.

In addition, Eno, Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology's annual scientific conference on March 28-30. At this premier cardiology event, the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners. This conference participation is significant as it provides direct access to cardiologists who are key decision-makers in adopting new cardiac monitoring technologies.

The company's technology represents a potential shift in cardiac care delivery. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians could potentially identify cardiac health trends and acute conditions and direct patients to appropriate care—all outside of a medical facility.

HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement. The FDA clearance details for the HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment are available at https://www.heartbeam.com/indications. This regulatory milestone is crucial for commercial deployment and physician adoption of the technology.

The conference schedule indicates HeartBeam's strategic focus on both investment community engagement and medical professional outreach. By presenting at the Oppenheimer and ROTH investor conferences, the company aims to build financial support and market awareness for its growth trajectory. Simultaneously, participation in ACC.26 allows direct demonstration of their technology to the cardiology community that would ultimately prescribe and use their devices. This dual approach addresses both the capital needs for development and the clinical adoption necessary for commercial success.

The timing of these presentations follows recent regulatory achievements that position HeartBeam's technology for broader market entry. The ability to showcase a working prototype of the 12-lead ECG extended wear patch at ACC.26 provides tangible evidence of product development progress beyond the already cleared HeartBeam System. For investors and industry partners, these conferences offer opportunities to assess the company's technology, management execution, and market potential as remote cardiac monitoring gains importance in healthcare delivery models focused on preventive care and reduced hospital visits.